ERBB2 and breast carcinoma: The encouraging results in HER2 low-expressing breast cancer in the metastatic setting observed in the DESTINY-Breast 04 study with the antibody–drug conjugate, trastuzumab deruxtecan, will likely pave the way for the use of these agents in the early-stage setting [86].